Table 3.
Success rate between categories according obstetric history (Primary or Secondary RM).
| Category | LIT Group | No LIT Group) | P |
|---|---|---|---|
| Category 1 | Patients (n = 426) | Patients (n = 242) | |
| Primary RM, n (%) | 236/370 (63.8) | 51/157 (32.5) | <0.001 |
| Secondary RM, n (%) | 32/56 (57) | 28/85(32.9) | 0.008 |
| Category 2 | Patients (n = 167) | Patients (n = 52) | |
| Primary RM, n (%) | 90/139 (64.7) | 13/30 (43.3) | 0.018 |
| Secondary RM, n (%) | 14/28 (50) | 5/22(22.7) | 0.049 |
| Category 3 (n = 138) | Patients (n = 108) | Patients (n = 30) | |
| Primary RM, n (%) | 49/87 (56.8) | 9/18 (50) | 0.395 |
| Secondary RM, n (%) | 12/21 (57.1) | 7/12 (58.3) | 0.590 |
| Category 4 (n = 71) | Patients (n = 51) | Patients (n = 20) | |
| Primary RM, n (%) | 15/40 (37.5) | 2/16 (12.5) | 0.060 |
| Secondary RM, n (%) | 4/11 (36.3) | 0/4 (0) | 0.330 |
P < 0.05 was considered statistically significant, using Fisher’s exact-test or χ2 test when appropriate for categorical variables. LIT: lymphocyte immunotherapy. RM: recurrent miscarriage. n, number. Category 1: alloimmune factor positive; Category 2: alloimmune factor and thrombophilic factor: at least one positive test for thrombophilia (antiphospholipid syndrome and/or other hereditary thrombophilias with positive heterozygotic or homozygotic status); Category 3: alloimmune factor and autoimmune factor (at least one positive autoantibody, except patients with APS who were allocated to category 2. Category 4: alloimmune factor associated with at least one thrombophilia and at least one autoantibody.